全文获取类型
收费全文 | 3469126篇 |
免费 | 266423篇 |
国内免费 | 12718篇 |
专业分类
耳鼻咽喉 | 48059篇 |
儿科学 | 112150篇 |
妇产科学 | 95920篇 |
基础医学 | 500330篇 |
口腔科学 | 98530篇 |
临床医学 | 318297篇 |
内科学 | 659389篇 |
皮肤病学 | 75287篇 |
神经病学 | 273769篇 |
特种医学 | 132936篇 |
外国民族医学 | 972篇 |
外科学 | 518843篇 |
综合类 | 94698篇 |
现状与发展 | 36篇 |
一般理论 | 1302篇 |
预防医学 | 271970篇 |
眼科学 | 82351篇 |
药学 | 264410篇 |
121篇 | |
中国医学 | 12099篇 |
肿瘤学 | 186798篇 |
出版年
2019年 | 29725篇 |
2018年 | 39639篇 |
2017年 | 30703篇 |
2016年 | 33766篇 |
2015年 | 39634篇 |
2014年 | 54945篇 |
2013年 | 79564篇 |
2012年 | 109323篇 |
2011年 | 116451篇 |
2010年 | 69355篇 |
2009年 | 64862篇 |
2008年 | 107255篇 |
2007年 | 113664篇 |
2006年 | 114954篇 |
2005年 | 111977篇 |
2004年 | 106483篇 |
2003年 | 101747篇 |
2002年 | 98796篇 |
2001年 | 153432篇 |
2000年 | 158139篇 |
1999年 | 133855篇 |
1998年 | 38040篇 |
1997年 | 33637篇 |
1996年 | 33026篇 |
1995年 | 33654篇 |
1994年 | 31200篇 |
1993年 | 29110篇 |
1992年 | 106333篇 |
1991年 | 104028篇 |
1990年 | 101483篇 |
1989年 | 97952篇 |
1988年 | 90638篇 |
1987年 | 88958篇 |
1986年 | 84040篇 |
1985年 | 80928篇 |
1984年 | 60515篇 |
1983年 | 51859篇 |
1982年 | 30709篇 |
1979年 | 56757篇 |
1978年 | 40134篇 |
1977年 | 33607篇 |
1976年 | 32058篇 |
1975年 | 34287篇 |
1974年 | 41545篇 |
1973年 | 39744篇 |
1972年 | 37113篇 |
1971年 | 35046篇 |
1970年 | 32312篇 |
1969年 | 30698篇 |
1968年 | 28075篇 |
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
91.
Evaluation of the Role of Merromoside from Ipomoea aquatica Forsskal Hydroalcoholic Extract in the Downregulation of ROS Species in Overcoming MDR in Breast Cancer 下载免费PDF全文
Sasikala MMohan SSwarnakumari SNagarajan A 《Asian Pacific journal of cancer prevention》2022,23(11):3657-3663
Purpose: The medicinal plant Ipomoea aquatica belonging to convulvulaceae family is an effective natural herb for treatment of various ailments and possesses effective anticancer activity. The aim of the work is to characterize a secondary metabolite merromoside (a resin glycoside) for anti-breast cancer activity through down regulation of ROS species. Methods: The Extract of the whole plant has been prepared by maceration method using 50%v/v ethanol in distilled water to get a hydroalcoholic extract. The phytochemical evaluation reveals that the active secondary metabolite was isolated by using column chromatographic technique. The isolated compound was evaluated for its anticancer properties through invitro method such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay on Michigan Cancer Foundation-7 Cell lines. The purity and structural characterization were done by high-performance thin layer chromatography, Fourier Transform Infrared Spectroscopy, Proton and13C Nuclear Magnetic Resonance spectroscopy and Liquid Chromatography–Mass Spectrometry. Results: The isolated compound (W04) from the derived extract showed Rf value of 0.79 that showed IC50 of 182.8μg/ml. The chemical structure of W04 has been confirmed as [4,5-dihydroxy-6-[5-hydroxy-2-methyl-4-(2-methylpropanoyloxy)-6-[(24,25,26-trihydroxy-5,23-dimethyl-9-oxo-19-pentyl-2,4,8,20,22-pentaoxatricyclo[19.2.2.13,7]hexacosan-6-yl)oxy]oxan-3-yl]oxy-2-methyloxan-3-yl] 2-methyl propanoate with the molecular weight of 979.15268. The isolated compound merromoside from hydroalcoholic extract of Ipomoea aquatica has been evaluated for anti-breast cancer properties. The down regulation of ROS species will prevent reverse signalling and angiogenesis. This indicates that merromoside will overcome MDR in breast cancer especially DOX-resistant. 相似文献
92.
93.
94.
95.
96.
97.
Osnat Bairey MD Alisa Taliansky MD Amir Glik MD Alexandra Amiel MD Shlomit Yust-Katz MD Ronit Gurion MD Miri Zektser MD Tzvika Porges MD Nadav Sarid MD Netanel A. Horowitz MD Tzahala Tzuk Shina MD Eyal Lebel MD Amos Cohen MD Karyn Revital Geiger MD Pia Raanani MD Ofir Wolach MD Tali Siegal MD 《Cancer》2023,129(24):3905-3914
98.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
99.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
100.